Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study.J Am Coll Cardiol. 2002; 40: 27-33
- The prognostic significance of early and late anaemia in acute coronary syndrome.QJM. 2012; 105: 445-454
- Anemia and mortality in acute coronary syndromes: a systematic review and meta-analysis.Am Heart J. 2013; 165: 143-153e5
- Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial).Am J Cardiol. 2014; 114: 1823-1829
- Additive effect of anemia and renal impairment on long-term outcome after percutaneous coronary intervention.PLoS One. 2014; 9: e114846
- Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting: a comparison with the matched general population.Circulation. 2009; 120: 118-125
- Anemia of chronic disease.N Engl J Med. 2005; 352: 1011-1023
- Inflammation and immunity in diseases of the arterial tree: players and layers.Circ Res. 2015; 116: 307-311
- Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function.Clin Cardiol. 2013; 36: 611-620
- The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review.Congest Heart Fail. 2009; 15: 123-130
- Impact of chronic kidney disease on use of evidence-based therapy in stable coronary artery disease: a prospective analysis of 22,272 patients.PLoS One. 2014; 9: e102335
- Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry.Eur Heart J. 2012; 33: 2831-2840
- Gender- and age-related differences in clinical presentation and management of outpatients with stable coronary artery disease.Int J Cardiol. 2013; 167: 2938-2943
- Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY Registry.PLoS One. 2015; 10: e0125164
- Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.(Available at:)Accessed October 6, 2016)
- A new equation to estimate glomerular filtration rate.Ann Intern Med. 2009; 150: 604-612
- Anaemia to predict outcome in patients with acute coronary syndromes.Arch Cardiovasc Dis. 2013; 106: 357-365
- Prognostic impact of anaemia on patients with ST-elevation myocardial infarction treated by primary PCI.Coron Artery Dis. 2014; 25: 52-59
- Predictors of long term outcomes in 11,441 consecutive patients following percutaneous coronary interventions.Am J Cardiol. 2015; 115: 855-859
- Anemia as independent predictor of major events in elderly patients with chronic angina.Am Heart J. 2006; 152: 991-996
- Anaemia predicts cardiovascular events in patients with stable coronary artery disease.Neth Heart J. 2005; 13: 254-258
- Anemia and mortality in heart failure patients a systematic review and meta-analysis.J Am Coll Cardiol. 2008; 52: 818-827
- Hemoglobin nonrecovery following acute myocardial infarction is a biomarker of poor outcome: a retrospective database study.Int J Cardiol. 2013; 169: 349-353
- Perils and pitfalls of long-term effects of proton pump inhibitors.Expert Rev Clin Pharmacol. 2013; 6: 443-451
- Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients.Circ J. 2015; 79: 193-200
- Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease.Circulation. 2008; 117: 163-168
Funding: This work was supported by research grants from Servier, France. The study was designed and conducted by the investigators. All data were collected and analyzed by NG and IF at the independent academic statistics center at the Robertson Centre for Biostatistics at the University of Glasgow, United Kingdom, and interpreted by the investigators. The sponsor had no role in the design and management of the study, in the analysis and interpretation of the data, and in the decision to submit the manuscript for publication, but did assist with the setup, data collection, and management of the study in each country. The sponsor funded editorial support for editing and revision of the manuscript and received the manuscript for review before submission. The ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease registry enforces a no ghostwriting policy.
Conflict of Interest: PRK reports personal fees from Servier, during the conduct of the study, and personal fees and other from Servier, Alere, Amgen, BMS, Janssen, Novartis, Pfizer, Pharmacosmos, Vifor and research grants from Servier, Alere and Pharmacosmos outside the submitted work. NG reports grants from Servier during the conduct of the study. RF reports grants and personal fees from Servier and Novartis, personal fees from Merck Serono, grants and personal fees from Boehringer Ingelheim, grants from Irbtech, and personal fees from Amgen, outside the submitted work. IF reports grants and personal fees from Servier, during the conduct of the study, and grants and personal fees from Amgen, outside the submitted work. J-CT reports grants from Servier, during the conduct of the study, grants and other from Servier, grants from Roche, grants and other from Pfizer, grants from AstraZeneca and Merck, grants and other from Sanofi, grants from Eli-Lilly, grants and other from Thrasos, grants from Valeant, and other from Takeda, outside the submitted work. MT reports personal fees from Servier during the conduct of the study, personal fees from Bayer, Celyad, Janssen-Cilag, Novartis, Servier, and Stealth Biotherapeutics, and grants from Polish National Center for Research and Development outside the submitted work. ND reports grants, personal fees, and nonfinancial support from Amgen, grants, personal fees, and nonfinancial support from AstraZeneca, grants and personal fees from Bayer and Daiichi Sankyo, grants, personal fees, and nonfinancial support from Eli Lilly, personal fees from GSK, grants and personal fees from MSD, personal fees from Novartis, Novo-Nordisk, Pfizer, and Roche, grants, personal fees, and nonfinancial support from Sanofi, personal fees and nonfinancial support from Servier, and personal fees from BMS and Boehringer Ingelheim, during the conduct of the study. JS reports grants from Novartis, grants, personal fees, and nonfinancial support from Servier, personal fees from Abbott, AstraZeneca, and Bayer, personal fees and nonfinancial support from Boehringer Ingelheim, and personal fees from Elli Lilly, Sanofi, and Amgen, outside the submitted work. PGS reports grants and personal fees from Servier, during the conduct of the study, personal fees from Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi-Sankyo, GlaxoSmithKline, Lilly, Merck-Sharpe-Dohme, Novartis, Pfizer, and Roche, grants and personal fees from Sanofi and Servier, personal fees from Janssen, personal fees and nonfinancial support from The Medicines Company, and personal fees from Regado and Regeneron, outside the submitted work. KMF reports personal fees from Servier, nonfinancial support from Servier, during the conduct of the study, personal fees and nonfinancial support from Servier, personal fees from AstraZeneca and TaurX, nonfinancial support from Armgo, personal fees and nonfinancial support from Broadview Ventures, personal fees from CellAegis, outside the submitted work; and Director of Heart Research Ltd and Vesalius Trials Ltd; minimal stockholder of Armgo and CellAegis.
Authorship: All authors had access to the data and played a role in writing this manuscript.